<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12093">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00518089</url>
  </required_header>
  <id_info>
    <org_study_id>198782-005</org_study_id>
    <nct_id>NCT00518089</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will determine the safety and efficacy of gatifloxacin eye drops in patients with
      bacterial conjunctivitis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge Up to Day 6</measure>
    <time_frame>6 Days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of patients that achieved clinical success, defined as achievement of a score of zero for both conjunctival hyperemia and conjunctival discharge in the study eye up to Day 6. Conjunctival hyperemia and conjunctival discharge were each assessed on a 4-point severity grade scale (0=none, +1=mild, +2=moderate, +3=severe).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge at Day 6</measure>
    <time_frame>Day 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of patients that achieved clinical success, defined as achievement of a score of zero for both conjunctival hyperemia and conjunctival discharge in the study eye at Day 6. Conjunctival hyperemia and conjunctival discharge were each assessed on a 4-point severity grade scale (0=none, +1=mild, +2=moderate, +3=severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Microbiological Cure Up to Day 6</measure>
    <time_frame>6 Days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of patients with microbiological cure, defined such that all bacteria present in the study eye at Day 1 (Baseline) are eradicated up to Day 6 based on a Classification of Microbial Response. (Eradication=pathogen is absent in follow-up culture; Reduction=pathogen is reduced from baseline below threshold count in follow-up culture; Persistence=pathogen reduced from baseline but is above or equal to threshold count in follow-up culture; and Proliferation=pathogen has increased in count from baseline in follow-up culture).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Clinical Improvement of Ocular Signs Up to Day 6</measure>
    <time_frame>6 Days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of patients with clinical improvement of ocular signs up to Day 6 based on a 4-point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe), defined as a decrease (improvement) from Day 1 (Baseline) in the total score of conjunctival hyperemia and mucopurulent discharge (pus), with no increase (worsening) from Day 1 (Baseline) in either individual variable in the study eye.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Clinical Improvement of Ocular Symptoms Up to Day 6</measure>
    <time_frame>6 Days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of patients with clinical improvement of ocular symptoms, defined as a decrease (improvement) up to Day 6 from Day 1 (Baseline) in the total score of itching and tearing (each on 4-point scale: 0 = none, 1 = mild, 2 = moderate, and 3 = severe), with no increase (worsening) from Day 1 (Baseline) in any individual score in the study eye diagnosed with bacterial conjunctivitis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">859</enrollment>
  <condition>Bacterial Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>Gatifloxacin 0.5% Eye Drops</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gatifloxacin 0.5% Eye Drops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Eye Drops</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Eye Drops</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gatifloxacin 0.5% eye drops</intervention_name>
    <description>Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily</description>
    <arm_group_label>Gatifloxacin 0.5% Eye Drops</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo eye drops</intervention_name>
    <description>Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily</description>
    <arm_group_label>Placebo Eye Drops</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically diagnosed with bacterial conjunctivitis

        Exclusion Criteria:

          -  Signs and/or symptoms of conjunctivitis for more than 96 hours

          -  Signs and/or symptoms suggestive of fungal, viral, or allergic conjunctivitis

          -  Clinical diagnosis of chlamydia in either eye
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Downey</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rajajinagar</city>
        <state>Bangalore</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <lastchanged_date>October 24, 2011</lastchanged_date>
  <firstreceived_date>August 16, 2007</firstreceived_date>
  <firstreceived_results_date>June 15, 2010</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gatifloxacin</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gatifloxacin 0.5% Eye Drops</title>
        </group>
        <group group_id="P2">
          <title>Placebo Eye Drops</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="430"/>
                <participants group_id="P2" count="429"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="402"/>
                <participants group_id="P2" count="398"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gatifloxacin 0.5% Eye Drops</title>
        </group>
        <group group_id="B2">
          <title>Placebo Eye Drops</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="430"/>
                <measurement group_id="B2" value="429"/>
                <measurement group_id="B3" value="859"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>1-18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="66"/>
                <measurement group_id="B2" value="74"/>
                <measurement group_id="B3" value="140"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>19-65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="316"/>
                <measurement group_id="B2" value="313"/>
                <measurement group_id="B3" value="629"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="48"/>
                <measurement group_id="B2" value="42"/>
                <measurement group_id="B3" value="90"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="183"/>
                <measurement group_id="B2" value="156"/>
                <measurement group_id="B3" value="339"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="247"/>
                <measurement group_id="B2" value="273"/>
                <measurement group_id="B3" value="520"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge at Day 6</title>
        <description>Percentage of patients that achieved clinical success, defined as achievement of a score of zero for both conjunctival hyperemia and conjunctival discharge in the study eye at Day 6. Conjunctival hyperemia and conjunctival discharge were each assessed on a 4-point severity grade scale (0=none, +1=mild, +2=moderate, +3=severe).</description>
        <time_frame>Day 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>Modified Intent to Treat; defined as all randomized patients who were &quot;culture positive&quot; at baseline meaning the culture of the eye grew bacteria. (Note: The Day 6 analysis included all Day 6 visit data, regardless of whether it was collected on Day 6 or on a later day).</population>
        <group_list>
          <group group_id="O1">
            <title>Gatifloxacin 0.5% Eye Drops</title>
          </group>
          <group group_id="O2">
            <title>Placebo Eye Drops</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="166"/>
                  <measurement group_id="O2" value="167"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge at Day 6</title>
            <description>Percentage of patients that achieved clinical success, defined as achievement of a score of zero for both conjunctival hyperemia and conjunctival discharge in the study eye at Day 6. Conjunctival hyperemia and conjunctival discharge were each assessed on a 4-point severity grade scale (0=none, +1=mild, +2=moderate, +3=severe).</description>
            <units>Percentage of Patients</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="59.6"/>
                  <measurement group_id="O2" value="46.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Microbiological Cure Up to Day 6</title>
        <description>Percentage of patients with microbiological cure, defined such that all bacteria present in the study eye at Day 1 (Baseline) are eradicated up to Day 6 based on a Classification of Microbial Response. (Eradication=pathogen is absent in follow-up culture; Reduction=pathogen is reduced from baseline below threshold count in follow-up culture; Persistence=pathogen reduced from baseline but is above or equal to threshold count in follow-up culture; and Proliferation=pathogen has increased in count from baseline in follow-up culture).</description>
        <time_frame>6 Days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Modified Intent to Treat; defined as all randomized patients who were &quot;culture positive&quot; at baseline meaning the culture of the eye grew bacteria. (Note: The &quot;Up to Day 6&quot; analysis included all data up to the Day 6 time point but excluded any Day 6 visit data that was collected after the Day 6 time point).</population>
        <group_list>
          <group group_id="O1">
            <title>Gatifloxacin 0.5% Eye Drops</title>
          </group>
          <group group_id="O2">
            <title>Placebo Eye Drops</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="166"/>
                  <measurement group_id="O2" value="167"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Patients With Microbiological Cure Up to Day 6</title>
            <description>Percentage of patients with microbiological cure, defined such that all bacteria present in the study eye at Day 1 (Baseline) are eradicated up to Day 6 based on a Classification of Microbial Response. (Eradication=pathogen is absent in follow-up culture; Reduction=pathogen is reduced from baseline below threshold count in follow-up culture; Persistence=pathogen reduced from baseline but is above or equal to threshold count in follow-up culture; and Proliferation=pathogen has increased in count from baseline in follow-up culture).</description>
            <units>Percentage of Patients</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="92.2"/>
                  <measurement group_id="O2" value="80.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Clinical Improvement of Ocular Signs Up to Day 6</title>
        <description>Percentage of patients with clinical improvement of ocular signs up to Day 6 based on a 4-point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe), defined as a decrease (improvement) from Day 1 (Baseline) in the total score of conjunctival hyperemia and mucopurulent discharge (pus), with no increase (worsening) from Day 1 (Baseline) in either individual variable in the study eye.</description>
        <time_frame>6 Days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Modified Intent to Treat; defined as all randomized patients who were &quot;culture positive&quot; at baseline meaning the culture of the eye grew bacteria. (Note: The &quot;Up to Day 6&quot; analysis included all data up to the Day 6 time point but excluded any Day 6 visit data that was collected after the Day 6 time point).</population>
        <group_list>
          <group group_id="O1">
            <title>Gatifloxacin 0.5% Eye Drops</title>
          </group>
          <group group_id="O2">
            <title>Placebo Eye Drops</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="166"/>
                  <measurement group_id="O2" value="167"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Patients With Clinical Improvement of Ocular Signs Up to Day 6</title>
            <description>Percentage of patients with clinical improvement of ocular signs up to Day 6 based on a 4-point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe), defined as a decrease (improvement) from Day 1 (Baseline) in the total score of conjunctival hyperemia and mucopurulent discharge (pus), with no increase (worsening) from Day 1 (Baseline) in either individual variable in the study eye.</description>
            <units>Percentage of Patients</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="97.0"/>
                  <measurement group_id="O2" value="92.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Clinical Improvement of Ocular Symptoms Up to Day 6</title>
        <description>Percentage of patients with clinical improvement of ocular symptoms, defined as a decrease (improvement) up to Day 6 from Day 1 (Baseline) in the total score of itching and tearing (each on 4-point scale: 0 = none, 1 = mild, 2 = moderate, and 3 = severe), with no increase (worsening) from Day 1 (Baseline) in any individual score in the study eye diagnosed with bacterial conjunctivitis.</description>
        <time_frame>6 Days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Modified Intent to Treat; defined as all randomized patients who were &quot;culture positive&quot; at baseline meaning the culture of the eye grew bacteria. (Note: The &quot;Up to Day 6&quot; analysis included all data up to the Day 6 time point but excluded any Day 6 visit data that was collected after the Day 6 time point).</population>
        <group_list>
          <group group_id="O1">
            <title>Gatifloxacin 0.5% Eye Drops</title>
          </group>
          <group group_id="O2">
            <title>Placebo Eye Drops</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="166"/>
                  <measurement group_id="O2" value="167"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Patients With Clinical Improvement of Ocular Symptoms Up to Day 6</title>
            <description>Percentage of patients with clinical improvement of ocular symptoms, defined as a decrease (improvement) up to Day 6 from Day 1 (Baseline) in the total score of itching and tearing (each on 4-point scale: 0 = none, 1 = mild, 2 = moderate, and 3 = severe), with no increase (worsening) from Day 1 (Baseline) in any individual score in the study eye diagnosed with bacterial conjunctivitis.</description>
            <units>Percentage of Patients</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="92.8"/>
                  <measurement group_id="O2" value="88.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge Up to Day 6</title>
        <description>Percentage of patients that achieved clinical success, defined as achievement of a score of zero for both conjunctival hyperemia and conjunctival discharge in the study eye up to Day 6. Conjunctival hyperemia and conjunctival discharge were each assessed on a 4-point severity grade scale (0=none, +1=mild, +2=moderate, +3=severe).</description>
        <time_frame>6 Days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Modified Intent to Treat; defined as all randomized patients who were &quot;culture positive&quot; at baseline meaning the culture of the eye grew bacteria. (Note: The &quot;Up to Day 6&quot; analysis included all data up to the Day 6 time point but excluded any Day 6 visit data that was collected after the Day 6 time point).</population>
        <group_list>
          <group group_id="O1">
            <title>Gatifloxacin 0.5% Eye Drops</title>
          </group>
          <group group_id="O2">
            <title>Placebo Eye Drops</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="166"/>
                  <measurement group_id="O2" value="167"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge Up to Day 6</title>
            <description>Percentage of patients that achieved clinical success, defined as achievement of a score of zero for both conjunctival hyperemia and conjunctival discharge in the study eye up to Day 6. Conjunctival hyperemia and conjunctival discharge were each assessed on a 4-point severity grade scale (0=none, +1=mild, +2=moderate, +3=severe).</description>
            <units>Percentage of Patients</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="51.8"/>
                  <measurement group_id="O2" value="41.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety Population used for serious adverse event and adverse event analysis - defined as all patients who were randomized AND treated.</desc>
      <group_list>
        <group group_id="E1">
          <title>Gatifloxacin 0.5% Eye Drops</title>
        </group>
        <group group_id="E2">
          <title>Placebo Eye Drops</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Irritation</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="429"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>Allergan, Inc.</organization>
      <phone>(714) 246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
